VSIR and prostate carcinoma: Based on these observations, it was concluded that the addition of anti-VISTA therapy to the currently available immune checkpoint inhibitors represents a new frontier in immunotherapy for prostate cancer although further studies are required to clarify the mechanism by which VISTA functions as an immunosuppressive checkpoint [14].